Search results for "Dox"

showing 10 items of 1345 documents

Whole-body MRI radiomics model to predict relapsed/refractory Hodgkin Lymphoma: A preliminary study.

2022

Purpose A strong prognostic score that enables a stratification of newly diagnosed Hodgkin Lymphoma (HL) to identify patients at high risk of refractory/relapsed disease is still needed. Our aim was to investigate the potential value of a radiomics analysis pipeline from whole-body MRI (WB-MRI) exams for clinical outcome prediction in patients with Hodgkin Lymphoma (HL). Materials and methods Index lesions from baseline WB-MRIs of 40 patients (22 females; mean age 31.7 ± 11.4 years) with newly diagnosed HL treated by ABVD chemotherapy regimen were manually segmented on T1-weighted, STIR, and DWI images for texture analysis feature extraction. A machine learning approach based on the Extra T…

AdultPositron emission tomographymedicine.medical_specialtyWhole body mriBiomedical EngineeringBiophysicsVinblastineBleomycinYoung AdultRefractoryRadiomicsPositron Emission Tomography Computed TomographyMachine learningAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansRadiology Nuclear Medicine and imagingMagnetic resonance imaging Positron emission tomography Machine learning Texture analysis Hodgkin Lymphomamedicine.diagnostic_testHodgkin Lymphomabusiness.industryMagnetic resonance imagingMetabolic tumor volumeHodgkin DiseaseMagnetic Resonance ImagingDacarbazineTexture analysisPositron emission tomographyDoxorubicinRelapsed refractoryHodgkin lymphomaFemaleRadiologySettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessMagnetic resonance imaging
researchProduct

Paradoxical embolism through a patent foramen ovale from central venous catheter thrombosis: A potential cause of stroke

2020

Paradoxical embolism refers to a potential condition in which an embolus arising from a venous source crosses into the systemic circulation through a right-to-left cardiac shunt causing an arterial embolism. A 39-year-old woman carrier of a central venous catheter (CVC) without evident risk factors for stroke, developed an acute right homonymous hemianopia during hemodialysis. On neuroimaging, an infarct in the territory of the left posterior cerebral artery was demonstrated. Transesophageal echocardiography revealed a patent foramen ovale (PFO) and a large fluctuating thrombus in the right atrium on the tip of the CVC, thus allowing a diagnosis of ischemic stroke from paradoxical embolism.…

Adultmedicine.medical_specialtyArterial embolismCardioembolismmedicine.medical_treatmentEmbolismForamen Ovale Patent03 medical and health sciences0302 clinical medicineParadoxical embolismEmbolusUpper Extremity Deep Vein ThrombosisInternal medicinemedicineHumanscardiovascular diseases030212 general & internal medicineThrombusStrokebusiness.industryCardiac shuntmedicine.diseasePatent foramen ovaleStrokeNeurologyPatent foramen ovaleCardiologySettore MED/26 - NeurologiaFemaleNeurology (clinical)businessCentral venous catheterEchocardiography Transesophageal030217 neurology & neurosurgeryCentral venous catheterEmbolism ParadoxicalJournal of the Neurological Sciences
researchProduct

Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study

2007

Abstract Background The objective of this study is to evaluate the efficacy and toxicity of the liposome-encapsulated doxorubicin (TLC D-99) plus cyclophosphamide (CTX) as first-line treatment of metastatic breast cancer in light of the potential cardioprotective effect of TLC D-99 as compared with conventional doxorubicin. Materials and methods Sixty-seven patients as defined according Simon's two-stage phase II design were enrolled. They received TLC D-99 at the dosage of 60 mg/m2 plus CTX 600 mg/m2, with cycles repeated every 3 weeks. Cardiac function was assessed by ultrasonography at baseline and every two cycles. Results The principal characteristics of the 67 enrolled patients were a…

Adultmedicine.medical_specialtySkin NeoplasmsCyclophosphamideSettore MED/06 - Oncologia MedicaPhases of clinical researchBreast NeoplasmsSoft Tissue NeoplasmsAsymptomaticGastroenterologyDrug Delivery SystemsBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisHumansAntineoplastic Agents AlkylatingCyclophosphamideAgedAntibiotics AntineoplasticPerformance statusbusiness.industryHematologyMiddle Agedmedicine.diseasedoxorubicin cyclophosphamide breast cancerMetastatic breast cancerSurgeryOncologyDoxorubicinLiposomesToxicityCarcinoma Squamous CellFemalemedicine.symptombusinessmedicine.drug
researchProduct

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Inn…

2007

To evaluate in a prospective multicenter trial the feasibility and clinical efficacy of the combination of alemtuzumab (Campath-1H) with the cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) regimen (CHOP-C) as the primary treatment for patients with peripheral T-cell lymphoma (PTCL), between January 2003 and December 2005, 24 consecutive patients with PTCL entered the study and received 8 CHOP courses. Alemtuzumab was added at 30 mg subcutaneously at day −1 initially to the first 4 courses (4 patients), and then to all 8 courses (20 patients). Complete remission (CR) was achieved in 17 (71%) patients, 1 had partial remission, and 6 had stable/progressive disease. At a median follo…

Adultmedicine.medical_specialtyVincristineAntibodies NeoplasmImmunologyKaplan-Meier EstimateCHOPAntibodies Monoclonal HumanizedBiochemistryGastroenterologyChemoimmunotherapyAntigens CDAntigens NeoplasmMulticenter trialInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansMulticenter Studies as TopicAlemtuzumabCyclophosphamideSocieties MedicalAgedGlycoproteinsDose-Response Relationship Drugbusiness.industryPralatrexateAntibodies MonoclonalLymphoma T-Cell PeripheralCell BiologyHematologyMiddle Agedmedicine.diseaseSurgeryRegimenCD52 AntigenItalyDoxorubicinVincristineAlemtuzumabPrednisonebusinessProgressive diseasemedicine.drug
researchProduct

The adverse redox biochemistry of intramembrane thiols accounts for the lifespan-dependent cysteine depletion in the inner mitochondrial membrane of …

2013

AgingEndocrinologyBiochemistryChemistryGeneticsCell BiologyInner mitochondrial membraneMolecular BiologyBiochemistryRedoxCysteineCell biologyExperimental Gerontology
researchProduct

PGC-1α, Inflammation, and Oxidative Stress: An Integrative View in Metabolism

2020

Peroxisome proliferator-activated receptor-γ coactivator (PGC)-1α is a transcriptional coactivator described as a master regulator of mitochondrial biogenesis and function, including oxidative phosphorylation and reactive oxygen species detoxification. PGC-1α is highly expressed in tissues with high energy demands, and it is clearly associated with the pathogenesis of metabolic syndrome and its principal complications including obesity, type 2 diabetes mellitus, cardiovascular disease, and hepatic steatosis. We herein review the molecular pathways regulated by PGC-1α, which connect oxidative stress and mitochondrial metabolism with inflammatory response and metabolic syndrome. PGC-1α regula…

AgingThioredoxin reductaseReview ArticleOxidative phosphorylationmedicine.disease_causeBiochemistryAntioxidantsCoactivatormedicineAnimalsHumansInflammationMetabolic Syndromechemistry.chemical_classificationReactive oxygen speciesOrganelle BiogenesisQH573-671ChemistryCell BiologyGeneral MedicinePeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaMitochondriaCell biologyOxidative StressMitochondrial biogenesisOrgan SpecificityThioredoxinCytologyPeroxiredoxinOxidative stressOxidative Medicine and Cellular Longevity
researchProduct

The Effect of Moderate- Versus High-Intensity Resistance Training on Systemic Redox State and DNA Damage in Healthy Older Women

2018

This study investigated effects of a 16-week progressive resistance training program (RTP) with elastic bands at two different intensities on systemic redox state, DNA damage, and physical function in healthy older women. Methods: Participants were randomly assigned to the high-intensity group (HIGH; n = 39), moderate-intensity group (MOD; n = 31), or control group (CG; n = 23). The exercise groups performed an RTP twice a week with three to four sets of 6 (HIGH) or 15 (MOD) repetitions of six overall body exercises at a perceived exertion rate of 8–9 on the OMNI-Resistance Exercise Scale for use with elastic bands. Thiol redox state was determined by reduced glutathione (GSH), oxidized gl…

Agingmedicine.medical_specialtyDNA damageStrength trainingEstrès oxidatiuUrinemedicine.disease_causeRedox03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineHumansDeoxyguanosineAgedAged 80 and overResearch and TheoryResistance trainingResistance Training030229 sport sciencesGlutathioneMiddle AgedEntrenament (Esport)GlutathioneHealthy VolunteersExercise TherapyEndocrinologychemistryFemaleOxidation-Reduction030217 neurology & neurosurgeryOxidative stressDNA Damage
researchProduct

Redox reaction between amino-(3,4-dihydroxyphenyl)methyl phosphonic acid and dopaquinone is responsible for the apparent inhibitory effect on tyrosin…

2002

Amino-(3,4-dihydroxyphenyl)methyl phosphonic acid, the phosphonic analog of 3,4-dihydroxyphenylglycine, had been previously reported as a potent inhibitor of tyrosinase. The mechanism of the apparent enzyme inhibition by this compound has now been established. Amino-(3,4-dihydroxyphenyl)methyl phosphonic acid turned out to be a substrate and was oxidized to o-quinone, which evolved to a final product identified as 3,4-dihydroxybenzaldehyde, the same as for 3,4-dihydroxyphenylglycine. Monohydroxylated compounds (amino-(3-hydroxyphenyl)methyl phosphonic acid and amino-(4-hydroxyphenyl)methyl phosphonic acid) were not oxidized, neither was 4-hydroxy-l-phenylglycine. However, the relatively hig…

Alaninechemistry.chemical_compoundNon-competitive inhibitionChemistryStereochemistryTyrosinaseDopachromeSubstrate (chemistry)TyrosineBiochemistryRedoxQuinoneEuropean Journal of Biochemistry
researchProduct

A Combination of Visible-Light Organophotoredox Catalysis and Asymmetric Organocatalysis for the Enantioselective Mannich Reaction of Dihydroquinoxal…

2019

[EN] An enantioselective photooxidative Mannich reaction of dihydroquinoxalinones with ketones by the merger of organophotoredox and asymmetric organocatalysis is described. This protocol features very mild reaction conditions using simple and cheap catalysts (Eosin Y and (S)-Proline) for the synthesis of chiral quinoxaline derivatives with good to high yields (up to 94%) and excellent enantioselectivities (up to 99% ee).

AlkylationActivation010402 general chemistry01 natural sciencesBiochemistryCatalysisReaccions químiqueschemistry.chemical_compoundQuinoxalineCatàlisiComplexesTertiary-AminesAcidOrganic chemistryPhysical and Theoretical ChemistryEosin YFunctionalizationMannich reactionReaction conditions010405 organic chemistryOrganic ChemistryEnantioselective synthesisMethodology0104 chemical sciencesPhotoredox catalysisEfficientchemistryOrganocatalysisFISICA APLICADAHydrogenationQuímica orgànicaVisible spectrum
researchProduct

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overvi…

2021

To date, four vaccines have been authorised for emergency use and under conditional approval by the European Medicines Agency to prevent COVID-19: Comirnaty, COVID-19 Vaccine Janssen, Spikevax (previously COVID-19 Vaccine Moderna) and Vaxzevria (previously COVID-19 Vaccine AstraZeneca). Although the benefit–risk profile of these vaccines was proven to be largely favourable in the general population, evidence in special cohorts initially excluded from the pivotal trials, such as pregnant and breastfeeding women, children/adolescents, immunocompromised people and persons with a history of allergy or previous SARS-CoV-2 infection, is still limited. In this narrative review, we critically overv…

AllergyIMPACTCOVID-19 VaccineBreastfeedingReview ArticleToxicologySettore MED/42 - Igiene Generale E ApplicataCLINICAL CHARACTERISTICSPregnancyPharmacology (medical)Pregnancy Complications InfectiousChildOUTCOMESeducation.field_of_studyCANCERVaccinationEuropeCORONAVIRUS DISEASE 2019 CLINICAL CHARACTERISTICS CANCER RECIPIENTS SEVERITY OUTCOMES IMPACT RATESBreast FeedingChild PreschoolPractice Guidelines as TopicFemale2019-nCoV Vaccine mRNA-1273HumanAdultmedicine.medical_specialtyCOVID-19 Vaccines2019-nCoV Vaccine mRNA-1273; Adolescent; Adult; BNT162 Vaccine; Breast Feeding; COVID-19; COVID-19 Vaccines; ChAdOx1 nCoV-19; Child; Child Preschool; Europe; Female; Humans; Infant; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications Infectious; SARS-CoV-2; Hypersensitivity; Immunocompromised HostAdolescentSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PopulationMEDLINECORONAVIRUS DISEASE 2019Immunocompromised HostChAdOx1 nCoV-19medicineHypersensitivityHumansRATESeducationBNT162 VaccinePharmacologyPregnancybusiness.industrySARS-CoV-2COVID-19Infantmedicine.diseaseVaccine efficacyRECIPIENTSSEVERITYFamily medicinePregnancy Complications Infectioubusiness
researchProduct